Extracorporeal photopheresis for the treatment of Crohn's disease

Sharyle Fowler; Jennifer Jones; Peter R Hull; Subrata Ghosh

doi:10.1016/j.transci.2015.02.006

Extracorporeal photopheresis for the treatment of Crohn's disease

Sharyle Fowler
, Jennifer Jones
, Peter R Hull
, Subrata Ghosh

Immunology and Immunotherapy

Research output: Contribution to journal › Review article › peer-review

2 Citations (Scopus)

Abstract

Small, open-label studies show promising results for ECP in the treatment of steroid-dependent and medically-refractory Crohn's disease. However, proper randomized, sham-controlled trials have not yet been performed. Based on the proposed mechanism of action of ECP, induction of a tolerogenic T cell response, ECP should be assessed in patients with early inflammatory disease rather than those who have progressed to fibrotic or stricturing disease. Randomized, sham-controlled trials need to be performed before ECP can be incorporated into standard clinical practice for the treatment of Crohn's disease.

Original language	English
Pages (from-to)	183-186
Number of pages	4
Journal	Transfusion and Apheresis Science
Volume	52
Issue number	2
Early online date	15 Feb 2015
DOIs	https://doi.org/10.1016/j.transci.2015.02.006
Publication status	Published - Apr 2015

Keywords

Blood Component Removal
Clinical Trials as Topic
Crohn Disease
Humans
Immunosuppressive Agents
Inflammation
Photopheresis
Research Design
Steroids
T-Lymphocytes
Treatment Outcome
Journal Article
Review

Access to Document

10.1016/j.transci.2015.02.006Licence: None: All rights reserved

https://www.sciencedirect.com/science/article/pii/S1473050215000178?via%3DihubLicence: None: All rights reserved

Cite this

@article{39156c3d81d942c4b743dde96f24db0e,

title = "Extracorporeal photopheresis for the treatment of Crohn's disease",

abstract = "Small, open-label studies show promising results for ECP in the treatment of steroid-dependent and medically-refractory Crohn's disease. However, proper randomized, sham-controlled trials have not yet been performed. Based on the proposed mechanism of action of ECP, induction of a tolerogenic T cell response, ECP should be assessed in patients with early inflammatory disease rather than those who have progressed to fibrotic or stricturing disease. Randomized, sham-controlled trials need to be performed before ECP can be incorporated into standard clinical practice for the treatment of Crohn's disease.",

keywords = "Blood Component Removal, Clinical Trials as Topic, Crohn Disease, Humans, Immunosuppressive Agents, Inflammation, Photopheresis, Research Design, Steroids, T-Lymphocytes, Treatment Outcome, Journal Article, Review",

author = "Sharyle Fowler and Jennifer Jones and Hull, \{Peter R\} and Subrata Ghosh",

year = "2015",

month = apr,

doi = "10.1016/j.transci.2015.02.006",

language = "English",

volume = "52",

pages = "183--186",

journal = "Transfusion and Apheresis Science",

issn = "1473-0502",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Extracorporeal photopheresis for the treatment of Crohn's disease

AU - Fowler, Sharyle

AU - Jones, Jennifer

AU - Hull, Peter R

AU - Ghosh, Subrata

PY - 2015/4

Y1 - 2015/4

N2 - Small, open-label studies show promising results for ECP in the treatment of steroid-dependent and medically-refractory Crohn's disease. However, proper randomized, sham-controlled trials have not yet been performed. Based on the proposed mechanism of action of ECP, induction of a tolerogenic T cell response, ECP should be assessed in patients with early inflammatory disease rather than those who have progressed to fibrotic or stricturing disease. Randomized, sham-controlled trials need to be performed before ECP can be incorporated into standard clinical practice for the treatment of Crohn's disease.

AB - Small, open-label studies show promising results for ECP in the treatment of steroid-dependent and medically-refractory Crohn's disease. However, proper randomized, sham-controlled trials have not yet been performed. Based on the proposed mechanism of action of ECP, induction of a tolerogenic T cell response, ECP should be assessed in patients with early inflammatory disease rather than those who have progressed to fibrotic or stricturing disease. Randomized, sham-controlled trials need to be performed before ECP can be incorporated into standard clinical practice for the treatment of Crohn's disease.

KW - Blood Component Removal

KW - Clinical Trials as Topic

KW - Crohn Disease

KW - Humans

KW - Immunosuppressive Agents

KW - Inflammation

KW - Photopheresis

KW - Research Design

KW - Steroids

KW - T-Lymphocytes

KW - Treatment Outcome

KW - Journal Article

KW - Review

U2 - 10.1016/j.transci.2015.02.006

DO - 10.1016/j.transci.2015.02.006

M3 - Review article

C2 - 25747960

SN - 1473-0502

VL - 52

SP - 183

EP - 186

JO - Transfusion and Apheresis Science

JF - Transfusion and Apheresis Science

IS - 2

ER -

Extracorporeal photopheresis for the treatment of Crohn's disease

Abstract

Keywords

Access to Document

Fingerprint

Cite this